University of Cambridge researchers have described the technique that is enable to reprogram adult mammalian cells into authentic induced pluripotent stem (iPS) cells. The finding has been published in the PLoS Biology, the peer-reviewed scientific journal from the Public Library of Science (PLoS)(1).

The newly described technique, was developed by Professor Austin Smith and his team at the University of Cambridge.It features a key proprietary step that forms the basis of a licence agreement signed recently between Stem Cell Sciences plc, and Cambridge Enterprise, the technology transfer company for the University of Cambridge.

This rapid and reliable new approach for generating pluripotent stem cells without using mammalian embryos uses the combination of chemical inhibitors in SCS’ Culticell iSTEM(TM) media range to overcome serious limitations in current approaches for producing such cells. Induced pluripotent stem cells are expected to have enormous potential in medical research, drug discovery and for the development of cell-based therapies.Dr Tim Allsopp, Chief Scientific Officer of Stem Cell Sciences, commented,

“This proprietary technique greatly facilitates the simple, most reliable and efficient route to obtaining authentic induced pluripotent stem cells and will form the basis for the industrialization of iPS cell production. This peer-reviewed publication is an important validation of the technology Professor Smith and his team have developed and Stem Cell Sciences is very pleased to be working with Cambridge University and Professor Smith’s team on this important breakthrough.”

About Stem Cell Sciences plc
Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Source: MarketWatch